Valuation: BioNTech SE

Market Cap 20.24B 23.16B 18.68B 17.21B 32.45B 2,230B 33.17B 223B 87.8B 1,092B 86.98B 85.07B 3,760B P/E 2026 *
-18.2x
P/E 2027 * -17.5x
Enterprise Value 9.38B 10.74B 8.66B 7.98B 15.04B 1,034B 15.38B 104B 40.71B 506B 40.33B 39.44B 1,744B EV / Sales 2026 *
4.33x
EV / Sales 2027 * 4.91x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-0.09%
1 week-0.01%
Current month-1.69%
1 month-0.80%
3 months-11.12%
6 months-13.34%
Current year-3.91%
1 week 88.35
Extreme 88.35
92.76
1 month 88.35
Extreme 88.35
98.81
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
464
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
12/5/26 Free

Executive/Senior Manager

22,655 0.0094%
12/5/26 Free

Chief Operating Officer

22,655 0.0094%
12/5/26 Free

Chief Financial Officer

33,982 0.0141%
Change 5-day change 1-year change 3-year change Capi.($)
-0.09%-0.01%-17.62%-14.67% 23.15B
-7.17%-2.63%+49.59%+74.24% 55.98B
+0.24%-5.62%+54.73%+125.15% 53.69B
+0.80%-6.31%+3.98%+423.29% 23.29B
-5.95%-0.22%+35.96%-9.58% 20.58B
-1.14%-3.16%+32.88%-28.80% 17.76B
-5.16%-7.00%+177.56%+326.39% 16.09B
-6.91%+2.40%+36.86%+636.97% 15.93B
+0.43%-1.03%+24.63%+191.40% 14B
+1.46%+3.13%+58.71%+148.16% 12.58B
Average -2.33%-1.39%+45.73%+187.25% 25.31B
Weighted average by Cap. -2.69%-2.22%+44.46%+156.60%

Financials

2026 *2027 *
Net sales 2.17B 2.48B 2B 1.84B 3.48B 239B 3.55B 23.91B 9.4B 117B 9.32B 9.11B 403B 2.23B 2.55B 2.06B 1.9B 3.58B 246B 3.66B 24.6B 9.68B 120B 9.59B 9.38B 414B
Net income -1.04B -1.19B -962M -886M -1.67B -115B -1.71B -11.49B -4.52B -56.25B -4.48B -4.38B -194B -1.16B -1.33B -1.07B -991M -1.87B -128B -1.91B -12.85B -5.05B -62.86B -5B -4.9B -216B
Net Debt -10.85B -12.42B -10.02B -9.23B -17.4B -1,196B -17.79B -120B -47.09B -586B -46.65B -45.62B -2,017B -9.29B -10.63B -8.57B -7.9B -14.89B -1,023B -15.22B -102B -40.28B -501B -39.9B -39.03B -1,725B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
18/07/26 USD 91.48 -0.09% 1,131,032
16/07/26 USD 91.56 -0.47% 670,293
15/07/26 USD 91.99 +1.76% 761,875
14/07/26 USD 90.40 +0.37% 923,470
13/07/26 USD 90.07 -1.55% 671,508
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
80.03EUR
Average target price
106.79EUR
Spread / Average Target
+33.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock